Hangzhou Shengshi Biotech

Hangzhou Shengshi Biotech is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative biologics and high-quality biosimilars. The company focuses on therapeutic areas including ophthalmology, oncology, and autoimmune diseases, leveraging its proprietary antibody engineering and expression platforms. Its lead programs include biosimilars for blockbuster drugs like aflibercept and pembrolizumab, as well as novel bispecific antibodies. Shengshi Biotech aims to provide affordable and effective biological treatments to patients globally through its integrated R&D and manufacturing capabilities.